Abstract
The data on the efficacy of atenolol for long-QT syndrome (LQTS) are controversial. This study aimed to evaluate the efficacy of atenolol for pediatric patients with LQTS. A retrospective observational study investigating all patients who had LQTS treated with atenolol at two institutions was performed. The study identified 57 patients (23 boys and 34 girls) with a mean QT corrected for heart rate (QTc) of 521 ± 54 ms. The mean age of these patients at diagnosis was 9 ± 6 years. Their clinical manifestations included no symptoms (n = 33, 58%), ventricular tachycardia (n = 10, 18%), syncope (n = 6, 10%), resuscitated sudden cardiac death (n = 4, 7%), atrioventricular block (n = 2, 4%), and bradycardia or presyncope (n = 2, 3%). Of the 57 patients, 13 (22%) had a family history of sudden death. The follow-up period was 5.4 ± 4.5 years. Atenolol at a mean dose of 1.4 ± 0.5 mg/kg/day was administered twice a day for all the patients. The mean maximum heart rate was 132 ± 27 bpm on Holter monitors and 155 ± 16 bpm on exercise treadmill tests, with medication doses titrated up to achieve a maximum heart rate lower than 150 bpm on both tests. During the follow-up period, one patient died (noncompliant with atenolol at the time of death), and the remaining patients had no sudden cardiac death events. Four patients (8%) had recurrent ventricular arrhythmias, three of whom received an implantable cardioverter defibrillator (all symptomatic at the time of diagnosis). For three patients (6%), it was necessary to rotate to a different beta-blocker because of side effects or inadequate heart rate control. Atenolol administered twice daily constitutes a valid and effective alternative for the treatment of pediatric patients with LQTS.
Similar content being viewed by others
References
Chatrath R, Bell CM, Ackerman MJ (2004) Beta-blocker therapy failures in symptomatic probands with genotyped long QT syndrome. Pediatr Cardiol 25:459–465
Goldenberg I, Moss AJ, Peterson DR, McNitt S, Zareba W, Andrews ML, Robinson JL, Locati EH, Ackerman MJ, Benhorin J, Kaufman ES, Napolitano C, Priori SG, Qi M, Schwartz PJ, Towbin JA, Vincent GM, Zhang L (2008) Risk factors for aborted cardiac arrest and sudden cardiac death in children with the congenital long QT syndrome. Circulation 117:2184–2191
Kirch W, Görg KG (1982) Clinical pharmacokinetics of atenolol: a review. Eur J Drug Metab Pharmacokinet 7:81–91
Moss AJ, Zareba W, Hall WJ, Schwartz PJ, Crampton RS, Benhorin J, Vincent GM, Locati EH, Priori SG, Napolitano C, Medina A, Zhang L, Robinson JL, Timothy K, Towbin JA, Andrews ML (2000) Effectiveness and limitations of beta-blocker therapy in congenital long QT syndrome. Circulation 101:616–623
Pellizzón OA, Kalaizich L, Ptácek LJ, Tristani-Firouzi M, Gonzalez MD (2008) Flecainide suppresses bidirectional ventricular tachycardia and reverses tachycardia-induced cardiomyopathy in Andersen-Twail syndrome. J Cardiovasc Electrophysiol 19:95–97
Priori SG, Schwartz PJ, Napolitano C, Bloise R, Ronchetti E, Grillo M, Vicentini A, Spazzolini C, Nastoli J, Bottelli G, Folli R, Cappelletti D (2003) Risk stratification in the long QT syndrome. N Engl J Med 348:1866–1874
Roden DM (2008) Clinical practice: long QT syndrome. N Engl J Med 358:169–176
Schulze-Bahr E, Fenge H, Etzrodt D, Haverkamp W, Mönnig G, Wedekind H, Breithardt G, Kehl HG (2004) Long QT syndrome and life-threatening arrhythmia in a newborn: molecular diagnosis and treatment response. Heart 90:13–16
Schwartz PJ, Priori SG, Cerrone M, Spazzolini C, Odero A, Napolitano C, Bloise R, De Ferrari GM, Klersy C, Moss AJ, Zareba W, Robinson JL, Hall WJ, Brink PA, Toivonen L, Epstein AE, Li C, Hu D (2004) Left cardiac sympathetic denervation in the management of high-risk patients affected by the long QT syndrome Circulation 109:1826–1833
Trippel DL, Gillette PC (1990) Atenolol in children with ventricular arrhythmias. Am Heart J 119:1312–1316
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Moltedo, J.M., Kim, J.J., Friedman, R.A. et al. Use of a Cardioselective Beta-Blocker for Pediatric Patients With Prolonged QT Syndrome. Pediatr Cardiol 32, 63–66 (2011). https://doi.org/10.1007/s00246-010-9819-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00246-010-9819-1